Cognition Therapeutics (CGTX) to Release Earnings on Thursday

Cognition Therapeutics (NASDAQ:CGTX) will likely be releasing its earnings data before the market opens on Thursday, March 20th. Analysts expect Cognition Therapeutics to post earnings of ($0.16) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Cognition Therapeutics Stock Down 1.5 %

Shares of CGTX stock opened at $0.44 on Wednesday. The stock has a fifty day moving average of $0.60 and a 200 day moving average of $0.55. Cognition Therapeutics has a 52 week low of $0.34 and a 52 week high of $2.95. The firm has a market capitalization of $18.29 million, a price-to-earnings ratio of -0.45 and a beta of 1.03.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CGTX. HC Wainwright raised their price target on Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, December 19th. Chardan Capital reaffirmed a “buy” rating and issued a $11.00 price target on shares of Cognition Therapeutics in a research note on Wednesday, February 26th. Brookline Capital Management raised Cognition Therapeutics to a “strong-buy” rating in a research note on Monday, January 27th. Finally, B. Riley raised Cognition Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $1.00 to $1.50 in a research report on Thursday, December 19th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Cognition Therapeutics currently has a consensus rating of “Buy” and an average price target of $8.30.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.